Impact of Substrate‐Based Ablation of Ventricular Tachycardia on Cardiac Mortality in Patients With Implantable Cardioverter‐Defibrillators

Abstract

LAVA elimination in addition to VT noninducibility as a procedural outcome for substrate-based ablation is associated with reduced mortality and better VT-free survival during follow-up. This prognostic benefit may be most pronounced in patients with severe heart failure as indicated by severely depressed LV function and NYHA class III/IV symptoms.